2023-10-11 06:35:02
Zurich (awp) – The pharmaceutical group Roche announced Wednesday that data collected during a phase III clinical study show that the drug Ocrevus, in an experimental subcutaneous injection version, is as effective as when the product is administered under intravenous form.
“We are pleased to see that Ocrevus as a 10-minute subcutaneous injection suppresses brain damage as effectively as the intravenous form,” said Levi Garraway, Roche’s medical director, quoted in the press release on Wednesday.
This new form could improve the quality of treatment for both patients and the medical profession. The subcutaneous injection should be administered twice a year.
Ocrevus is a medicine used to treat multiple sclerosis.
These data will be presented at a summit called ECTRIMS-ACTRIMS Meeting bringing together specialists from researchers focusing on multiple sclerosis.
ats/jh
lk/
1697012124
#Roche #positive #data #subcutaneous #injection #Ocrevus #October